Industry watchers who cheered on Summit Therapeutics’ claim that the first global phase 3 trial of its Akeso-partnered PD-1xVEGF drug showed consistent benefit between China and Western populations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results